Article Text

Download PDFPDF

698 A phase 2 study of durvalumab combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with oligometastatic non-small cell lung cancer (NSCLC) (SABRCURE trial)
  1. Ming Chen1,
  2. Honglian Ma2,
  3. Xianghui Du2,
  4. Yujin Xu2,
  5. Yongling Ji2 and
  6. Zhengbo Song2
  1. 1Sun Yat-sen University Cancer Center, Guangzhou, China
  2. 2Zhejiang Cancer Hospital, Hangzhou, China


Background Immunotherapy +/- chemotherapy is currently the standard of care for metastatic NSCLC, but strategies to expand the benefit are still needed. Oligometastatic NSCLC is a state of limited disease in which widespread metastasis has not yet evolved. Locally radiotherapy achieves prolonged progression- free survival and overall survival in a small proportion of well selected oligometastatic NSCLC patients1. Preliminary evidence suggests high dose fractionated radiotherapy, such as SBRT, in combination with systemic immunotherapy has a synergistic effect and may enhance survival2. Durvalumab (PD-L1 antibody) is approved as consolidation therapy for unresectable, locally advanced NSCLC who have not progressed following chemoradiotherapy. These findings support further investigation of durvalumab + SBRT combinations in oligometastatic NSCLC who received standard systematic therapy.

Methods SABRCURE is an open-label, phase 2 study evaluating the efficacy and safety of durvalumab combined with SBRT and chemotherapy in oligometastatic stage IV NSCLC. Key eligibility criteria include no more than 5 metastatic lesions in up to 3 organs, EGFR/ALK/ROS1 wild type, no previous systemic therapy or brain metastases. Forty patients will be enrolled and receive durvalumab 1500mg + platinum-doublet chemotherapy every 3 weeks for 4 cycles, and then durvalumab 1500mg every 4 weeks monotherapy until disease progression or up to 24 months. Patient without progression after 4 cycles durvalumab + chemotherapy will receive stereotactic body radiotherapy. SBRT will be started within 2 weeks after chemotherapy completion and administered to primary lesion and all known metastatic lesions, with a total dose of 50-60Gy in≤10 fractions. The primary endpoint is progression free survival (PFS) per RECIST v1.1. Secondary end points are objective response rate (ORR), overall survival (OS) , safety and treatment failure pattern. This study was funded by AstraZeneca China.

Trial Registration NCT04255836


  1. Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J. Clin. Oncol. 2019;37(18):1558.

  2. Azghadi S, Daly ME. Radiation and immunotherapy combinations in non-small cell lung cancer. Cancer Treatment and Research Communications. 2021;26:100298.

Ethics Approval This study was approved by Cancer Hospital of the University of Chinese Academy of Sciences Ethics Committee.

Consent Written informed consent was obtained from the patient for publication of this abstract.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.